Atrium Therapeutics Inc.
RNA | NASDAQ
$8.53
+$0.26 (+3.14%)
Nov 2, 2026, 2:35 PM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 |
|---|---|---|---|---|
Revenue | 23.5M | 20.49M | 859K | n/a |
Cost of Revenue | 494K | 151K | n/a | n/a |
Gross Profit | 23M | 20.34M | 859K | n/a |
Operating Income | -96.4M | -73.78M | -56.5M | -8.46M |
Interest Income | 2.1M | n/a | n/a | n/a |
Pretax Income | -93.32M | -73.13M | -56.5M | -8.46M |
Net Income | -93.18M | -72.99M | -56.36M | -8.29M |
Selling & General & Admin | 60.44M | 50.5M | 30.4M | n/a |
Research & Development | 50.5M | 35.15M | 18.5M | n/a |
Other Expenses | 8.46M | 8.46M | 8.46M | 8.46M |
Operating Expenses | 119.4M | 94.12M | 57.36M | 8.46M |
Interest Expense | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | -5.77M | -5.77M | -5.77M | -5.77M |
Cost & Expenses | 119.89M | 94.27M | 57.36M | 8.46M |
Income Tax Expense | -142K | -142K | -142K | -176K |
Shares Outstanding (Basic) | 17.11M | 17.11M | 17.11M | n/a |
Shares Outstanding (Diluted) | 17.11M | 17.11M | 17.11M | n/a |
EPS (Basic) | -3.85 | -2.67 | -1.70 | n/a |
EPS (Diluted) | -3.85 | -2.67 | -1.70 | n/a |
EBITDA | -95.06M | -72.79M | -56.31M | -8.39M |
EBIT | -95.75M | -73.13M | -56.5M | -8.46M |
Depreciation & Amortization | 685K | 342K | 191K | 69K |
Add to Watchlist
Select watchlists to add or remove RNA